Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, sold CTNM on Jul 1, 2026
Data as of Oct 27
▼ SELL$40.6K2,501 shares at $16.24Daniel S. Lorrain Chief Scientific OfficerCTNM Contineum Therapeutics, Inc.
- Traded
- Jul 1, 2026
- Disclosed
- Jul 2, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
CTNM since disclosure
−40.5%
after the sale
Similar stocks (XLV) since disclosure
+9.4%
XLV — its sector index fund
Change in closing price from Jul 2, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLDaniel S. Lorrain Chief Scientific OfficerCTNM Contineum Therapeutics, Inc.$91.7Kdisclosed Jul 2 · filed 1 day after the trade
- ▼ SELLDaniel S. Lorrain Chief Scientific OfficerCTNM Contineum Therapeutics, Inc.$462Kdisclosed Jul 2 · filed 2 days after the trade